RYAN PENROD: Open Payments
NPI 1205238870 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$445 in 18 payments from 10 companies in 2025. Trend: 2023 $682 · 2024 $318 · 2025 $445
Food & beverage: $365Education: $80
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $107 |
| Merck Sharp & Dohme LLC | 5 | $92 |
| Paratek Pharmaceuticals, Inc. | 1 | $61 |
| Aimmune Therapeutics, Inc. | 3 | $50 |
| Shionogi Inc | 2 | $36 |
| BioWound Solutions, Inc. | 1 | $29 |
| Insmed, Inc. | 1 | $25 |
| Gilead Sciences, Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Advanced Oxygen Therapy Inc. | 1 | $7 |
Products named: ZERBAXA, NUZYRA, VOWST, Fetroja, bio-ConneKt, Cresemba, Arikayce, Rezzayo.
Industry payments across AZ — which companies pay providers there.
